 |
| TEVA Pharmaceuticals Industries |
Teva Pharmaceutical Industries plans to acquire specialty drug maker Cephalon for $81.50 a share, topping an unsolicited bid by Canada's Valeant Pharmaceuticals International .
Teva (NASDAQ:TEVA) said the deal was worth about $6.8 billion on an enterprise basis.
The deal is worth about $6.2 billion, based on the number of Cephalon shares outstanding, according to Thomson Reuters data.
Stock of Cephalon is up more than 5 % to close to $ 81 in pre market trading while, stock of the TEVA pharmaceuticals is up more than 4% to $47.67 in pre market trade.
( Source: Thomson Reuters)
0 comments